A 2-year-old girl is found to have a firm, fixed, right-sided abdominal mass on examination. Ultrasound shows a heterogeneous suprarenal mass with calcifications. The child is asymptomatic with normal blood pressure. Which investigation is most appropriate to confirm the diagnosis of neuroblastoma and assess for metastatic disease?

Explanation

## Investigation of Choice for Neuroblastoma Diagnosis and Staging **Key Point:** Serum catecholamine metabolites (24-hour urine VMA and HVA) are the biochemical hallmark of neuroblastoma and provide diagnostic confirmation. MIBG (metaiodobenzylguanidine) scintigraphy is the gold standard for detecting metastatic disease because neuroblastoma cells avidly take up MIBG. ### Diagnostic and Staging Algorithm ```mermaid flowchart TD A[Suprarenal mass on imaging]:::outcome --> B[Measure 24-h urine VMA/HVA]:::action B --> C{Elevated?}:::decision C -->|Yes| D[Neuroblastoma highly likely]:::outcome C -->|No| E[Consider other diagnosis]:::outcome D --> F[MIBG scintigraphy]:::action F --> G[Assess for metastases]:::outcome G --> H[CT abdomen/pelvis for local staging]:::action H --> I[Bone marrow biopsy if high-risk]:::action ``` ### Why This Combination is Superior | Investigation | Purpose | Sensitivity | Specificity | |---------------|---------|-------------|-------------| | **24-h urine VMA/HVA** | Biochemical confirmation | 90–95% | >95% | | **MIBG scintigraphy** | Metastasis detection (bone, bone marrow, distant soft tissue) | 85–90% | Excellent | | **CT abdomen/pelvis** | Local tumor extent, lymph node involvement | Good | Supports staging | | **Bone marrow biopsy** | Detects occult metastases (high-risk disease) | Prognostic | Not diagnostic | **High-Yield:** Neuroblastoma produces catecholamine metabolites: - **VMA** (vanillylmandelic acid) — elevated in ~90% of cases. - **HVA** (homovanillic acid) — elevated in ~90% of cases. - **Dopamine** — elevated in some cases. These are the ONLY biochemical markers specific to neuroblastoma and are mandatory for diagnosis. **Clinical Pearl:** MIBG scintigraphy is superior to bone scan for neuroblastoma staging because: 1. It detects bone metastases (osteolytic and osteosclerotic). 2. It identifies bone marrow infiltration. 3. It shows soft-tissue metastases (liver, distant nodes). 4. It has higher sensitivity (85–90%) than bone scan (~70%) for neuroblastoma-specific sites. **Mnemonic:** **MIBG = Metastasis Imaging for Blastoma (neuro-) using Guanethidine analog** ### Role of Other Investigations **CT abdomen/pelvis:** Complements MIBG by defining: - Local tumor extent (invasion of adjacent organs, vascular involvement). - Lymph node involvement. - Contralateral adrenal involvement. - But CT does NOT replace MIBG for metastasis detection. **Bone marrow biopsy:** Performed in high-risk disease (age >18 months, stage 3/4, MYCN amplification) to detect occult metastases; not part of initial diagnostic workup. **Skeletal survey:** Insensitive for neuroblastoma bone metastases; MIBG is far superior.